一年一度2022美国临床肿瘤学会(ASCO)年会即将再次来临,此次会议已是58届,定于美国当地时间2022年06月03-07日举行。ASCO官网日前正式公布了本次会议的详细日程。作为肿瘤界首屈一指的交流盛会,每年的ASCO年会都会带来最前沿的肿瘤研究内容。让我们先看看今年入选ASCO妇科肿瘤的研究有哪些吧!具体研究摘要详情,请关注【肿瘤资讯】后续追踪。
口头报告大会
(Oral Abstract Session)
ATHENA–MONO (GOG-3020/ENGOT-ov45) :一项随机、双盲、3期试验,在一线铂类药物化疗后产生应答的卵巢癌患者中比较rucaparib单药治疗与安慰剂维持治疗
题目:ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer
汇报人:Bradley J. Monk
汇报时间:2022年6月6日星期一21:00(以下均为北京时间)
摘要号:LBA5500
一项在晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者中评价芦可替尼一线新辅助治疗和术后治疗的I/II期研究
题目:A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer
汇报人:Charles N. Landen
汇报时间:2022年6月6日星期一21:12
摘要号:5501
贝伐珠单抗一线化疗改善晚期卵巢透明细胞癌生存预后的多中心、回顾性研究
题目:Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis
汇报人:Toshiyuki Seki
汇报时间:2022年6月6日星期一21:24
摘要号:5502
在复发性铂耐药卵巢癌患者中,评价选择性糖皮质激素受体调节剂relacorilant联合白蛋白结合型紫杉醇的3组、随机、开放标签、2期研究的总生存期数据
题目:Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
汇报人:Nicoletta Colombo
汇报时间:2022年6月6日星期一22:00
摘要号:LBA5503
trabectedin(ET-743)单药与临床医生选择化疗治疗BRCA突变或BRCAness表型的复发性卵巢癌、原发性腹膜癌或输卵管癌患者的随机III期试验(MITO23)
题目:Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)
汇报人:Giovanni Scambia,
汇报时间:2022年6月6日星期一22:12
摘要号:LBA5504
帕博利珠单抗、maveropepimut-S和低剂量环磷酰胺治疗晚期上皮性卵巢癌:PESCO试验1期和扩展队列的结果
题目:Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial
汇报人:Ana Veneziani
汇报时间:2022年6月6日星期一22:24
摘要号:5505
帕博利珠单抗+化疗治疗持续性、复发性或转移性宫颈癌患者:KEYNOTE-826的亚组分析
题目:Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826
汇报人:Krishnansu Sujata Tewari,
汇报时间:2022年6月6日星期一23:00
摘要号:5506
Tisotumab vedotin(TV)+帕博利珠单抗用于一线(1L)复发性或转移性宫颈癌(r/mCC):ENGOT Cx8/GOG 3024/innovaTV 205的中期结果
题目:Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
汇报人:Domenica Lorusso
汇报时间:2022年6月6日星期一23:12
摘要号:5507
妇科癌症患者的COVID-19:COVID-19和癌症联盟(CCC19)的初步报告
题目:COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).
汇报人:Alicia Beeghly-Fadiel,
汇报时间:2022年6月6日星期一23:24
摘要号:5508
治疗发展-分子靶向药物与肿瘤生物学
在晚期肾细胞癌(RCC)和卵巢肿瘤(OVC)受试者中进行的DS-6000a I期、两部分、多中心、首次人体(FIH)研究
题目:Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).
汇报人:Erika P. Hamilton
汇报时间:2022年6月7日星期二23:09
摘要号:3002
临床科学论坛
(Clinical Science Symposium)
一项AK104(一种抗PD-1和抗CTLA-4双特异性抗体)联合标准疗法一线治疗持续性、复发性或转移性宫颈癌(R/M CC)的研究
题目:A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
汇报人:湖南省肿瘤医院 王静教授
汇报时间:2022年6月5日星期日23:21
摘要号:106
Dostarlimab治疗dMMR/MSI-H或MMRp/MSS的晚期/复发性子宫内膜癌(EC):GARNET研究
题目:Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study
汇报人:Ana Oaknin
汇报时间:2022年6月7日星期二21:00
摘要号:5509
一项贝伐珠单抗、阿替利珠单抗和rucaparib联合治疗既往经治的复发性和进展性子宫内膜癌的开放标签、非随机、多中心II期试验
题目:An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer
汇报人:William Hampton Bradley
汇报时间:2022年6月7日星期二21:00
摘要号:5510
在子宫内膜癌患者中比较selinexor维持治疗与安慰剂的随机III期研究(ENGOT-EN5/GOG-3055/SIENDO):亚组分析和分子分型的影响
题目:Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification
汇报人:Vicky Makker
汇报时间:2022年6月7日星期二21:00
摘要号:5511
NCI protocol 10250的相关结果:一项替莫唑胺和奥拉帕尼治疗晚期子宫平滑肌肉瘤的II期研究
题目:Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma
汇报人:Sminu Bos
汇报时间:2022年6月7日星期二02:15
摘要号:11509
排版编辑:肿瘤资讯-小V